Vaxcyte Inc (PCVX)

$73.65

-2.28

(-3%)

Market is closed - opens 7 PM, 22 May 2024

Performance

  • $73.64
    $75.58
    $73.65
    downward going graph

    0.02%

    Downside

    Day's Volatility :2.57%

    Upside

    2.55%

    downward going graph
  • $44.20
    $82.04
    $73.65
    downward going graph

    39.99%

    Downside

    52 Weeks Volatility :46.12%

    Upside

    10.23%

    downward going graph

Returns

PeriodVaxcyte IncSector (Health Care)Index (Russel 2000)
3 Months
5.08%
0.4%
0.0%
6 Months
49.59%
12.5%
0.0%
1 Year
53.46%
11.2%
0.0%
3 Years
259.69%
17.4%
-20.1%

Highlights

Market Capitalization
8.1B
Book Value
$18.24
Earnings Per Share (EPS)
-4.29
Wall Street Target Price
103.14
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-20.62%
Return On Equity TTM
-29.83%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-23.0M
EBITDA
-507.9M
Diluted Eps TTM
-4.29
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.04
EPS Estimate Next Year
-4.29
EPS Estimate Current Quarter
-1.17
EPS Estimate Next Quarter
-1.14

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Vaxcyte Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 40.04%

Current $73.65
Target $103.14

Technicals Summary

Sell

Neutral

Buy

Vaxcyte Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vaxcyte Inc
Vaxcyte Inc
23.26%
49.59%
53.46%
259.69%
259.69%
Moderna, Inc.
Moderna, Inc.
34.99%
82.8%
11.26%
-12.66%
521.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.68%
23.59%
31.37%
94.84%
218.53%
Novo Nordisk A/s
Novo Nordisk A/s
6.11%
29.32%
55.89%
226.96%
459.27%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.49%
25.68%
31.15%
108.91%
163.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vaxcyte Inc
Vaxcyte Inc
NA
NA
NA
-4.04
-0.3
-0.21
NA
18.24
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.98
28.98
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.48
45.48
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.91
28.91
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vaxcyte Inc
Vaxcyte Inc
Buy
$8.1B
259.69%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$50.9B
521.19%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.2B
218.53%
28.98
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$587.5B
459.27%
45.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$114.9B
163.64%
28.91
39.46%

Institutional Holdings

  • FMR Inc

    13.07%
  • Vanguard Group Inc

    8.95%
  • BlackRock Inc

    7.89%
  • RA Capital Management, LLC

    7.26%
  • HHG PLC

    7.06%
  • Wellington Management Company LLP

    4.08%

Corporate Announcements

  • Vaxcyte Inc Earnings

    Vaxcyte Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe

Organization
Vaxcyte Inc
Employees
254
CEO
Mr. Grant E. Pickering M.B.A.
Industry
Health Technology

FAQs